JAMPRO
30.9.2021 21:32:09 CEST | Business Wire | Press release
The Jamaica Promotions Corporation (JAMPRO) will be staging Explore: Do Business Jamaica Virtual Investment Conference (DBJVIC) from November 17 – 18, 2021 to introduce local and international investors to business opportunities in the island’s growing industries.
The event will showcase emerging projects and new developments in Agribusiness, Outsourcing, Manufacturing, Energy, Tourism, and the Creative Industries through over 30 panels, interviews and discussions with government and business leaders. The investment conference aims to foster business and stakeholder relationships and will shed light on Jamaica’s COVID-19 economic recovery efforts.
The conference will be staged concurrently via two platforms; one is a virtual interactive business event portal that will facilitate a real-time engagement experience and B2B meetings, the second is a live stream event via social media that will accommodate and drive increased awareness of Jamaica’s economic progress. This format will help JAMPRO to engage attendees including current and potential investors, JAMPRO clients, private and public sector stakeholders, and diplomatic missions.
JAMPRO anticipates extensive global participation based on the planned international promotions which will ensure the leveraging of the virtual B2B meeting platform by potential investors.
New opportunity to do business
Speaking on the event, Jamaica’s Minister of Industry, Investment, and Commerce, The Honourable Audley Shaw, CD, MP., noted that the virtual investment conference has presented a new opportunity for the government to amplify the promotion of Jamaica’s business opportunities.
He explained, “This virtual conference will allow us to reach and directly engage investors across the globe who are interested in doing business with Jamaica but need further market intelligence and guidance on the potential that is available in the island’s sectors. From our perspective, it is the right time to host this global event, as persons are seeking new ventures as the world slowly returns to normality .”
Diane Edwards, President of JAMPRO, echoed the Minister’s statements, and expressed confidence in the conference’s ability to deliver results for Jamaica and attendees, she said, “The format of the conference is powerful, because it presents an excellent opportunity for global business leaders to get valuable insight on Jamaican investment opportunities, engage their colleagues in various industries, and explore bankable projects, all in the location of their choice. We believe that this conference will lead to the development of lucrative partnerships and financial opportunities for local and international investors. ”
Persons can register for the event at explore.dobusinessjamaica.com
ABOUT THE EXPLORE: DO BUSINESS JAMAICA VIRTUAL INVESTMENT CONFERENCE (DBJVIC)
Explore: Do Business Jamaica Virtual Investment Conference is a 2-day event that will highlight investment and other business opportunities in Jamaica. The event, hosted by Jamaica’s investment and export promotion agency, JAMPRO, will provide a platform for attendees to learn more about Jamaican investment opportunities, see lucrative projects, and build business relationships.
Explore Do Business Jamaica Virtual Investment Conference is sponsored by the Foundations for Competitiveness and Growth Project (FCGP), National Commercial Bank (NCB), Mystique Integrated, and M-One Productions
For more information on the conference, please visit https://explore.dobusinessjamaica.com/ .
Follow JAMPRO on:
Twitter
Facebook
Instagram
LinkedIn
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005861/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom